View in EDS

Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial.

Saved in:
Bibliographic Details
Title: Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial.
Authors: Matasar M; Rutgers Cancer Institute, New Brunswick, NJ., Li Z; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China., Vassilakopoulos TP; National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece., Sancho JM; ICO-IJC-HU Germans Trias i Pujol, Barcelona, Spain., Viardot A; Department of Internal Medicine III, University Hospital, Ulm, Germany., McMillan A; Center for Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom., Dal MS; University of Health Science, Ankara Oncology Training and Research Hospital, Department of Internal Medicine, Division of Hematology and Stem Cell Transplant Center, Ankara, Turkey., Pereira J; Hospital das Clinicas FMUSP, São Paulo, Brazil., Kim JS; Severance Hospital, Yonsei University Health System, Seoul, South Korea., Qiu L; National Clinical Research Center for Hematological Disorders and State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China., Batlevi CL; Genentech, Inc, South San Francisco, CA., Ibrahim R; Genentech, Inc, South San Francisco, CA., Hernandez J; F. Hoffmann-La Roche Ltd, Basel, Switzerland., McCall B; Genentech, Inc, South San Francisco, CA., Jiang Y; Genentech, Inc, South San Francisco, CA., Yan M; Hoffmann-La Roche Ltd, Mississauga, ON, Canada., Harris W; Genentech, Inc, South San Francisco, CA., Musick L; Genentech, Inc, South San Francisco, CA., Haioun C; Lymphoid Malignancies Department, Henri Mondor University Hospital, Créteil Cedex, France.
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2026 Jul 06, pp. JCO2502849. Date of Electronic Publication: 2026 Jul 06.
Publication Type: Journal Article
Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42407012
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Matasar+M%22">Matasar M</searchLink>; Rutgers Cancer Institute, New Brunswick, NJ.<br /><searchLink fieldCode="AU" term="%22Li+Z%22">Li Z</searchLink>; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Vassilakopoulos+TP%22">Vassilakopoulos TP</searchLink>; National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece.<br /><searchLink fieldCode="AU" term="%22Sancho+JM%22">Sancho JM</searchLink>; ICO-IJC-HU Germans Trias i Pujol, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Viardot+A%22">Viardot A</searchLink>; Department of Internal Medicine III, University Hospital, Ulm, Germany.<br /><searchLink fieldCode="AU" term="%22McMillan+A%22">McMillan A</searchLink>; Center for Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Dal+MS%22">Dal MS</searchLink>; University of Health Science, Ankara Oncology Training and Research Hospital, Department of Internal Medicine, Division of Hematology and Stem Cell Transplant Center, Ankara, Turkey.<br /><searchLink fieldCode="AU" term="%22Pereira+J%22">Pereira J</searchLink>; Hospital das Clinicas FMUSP, São Paulo, Brazil.<br /><searchLink fieldCode="AU" term="%22Kim+JS%22">Kim JS</searchLink>; Severance Hospital, Yonsei University Health System, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Qiu+L%22">Qiu L</searchLink>; National Clinical Research Center for Hematological Disorders and State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China.<br /><searchLink fieldCode="AU" term="%22Batlevi+CL%22">Batlevi CL</searchLink>; Genentech, Inc, South San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Ibrahim+R%22">Ibrahim R</searchLink>; Genentech, Inc, South San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Hernandez+J%22">Hernandez J</searchLink>; F. Hoffmann-La Roche Ltd, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22McCall+B%22">McCall B</searchLink>; Genentech, Inc, South San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Jiang+Y%22">Jiang Y</searchLink>; Genentech, Inc, South San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Yan+M%22">Yan M</searchLink>; Hoffmann-La Roche Ltd, Mississauga, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Harris+W%22">Harris W</searchLink>; Genentech, Inc, South San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Musick+L%22">Musick L</searchLink>; Genentech, Inc, South San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Haioun+C%22">Haioun C</searchLink>; Lymphoid Malignancies Department, Henri Mondor University Hospital, Créteil Cedex, France.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228309333%22">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</searchLink> [J Clin Oncol] 2026 Jul 06, pp. JCO2502849. <i>Date of Electronic Publication: </i>2026 Jul 06.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Clinical+Oncology%22">American Society of Clinical Oncology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>8309333 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1527-7755 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220732183X%22">0732183X </searchLink><i>NLM ISO Abbreviation: </i>J Clin Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42407012
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1200/JCO-25-02849
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: JCO2502849
    Titles:
      – TitleFull: Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Matasar M
      – PersonEntity:
          Name:
            NameFull: Li Z
      – PersonEntity:
          Name:
            NameFull: Vassilakopoulos TP
      – PersonEntity:
          Name:
            NameFull: Sancho JM
      – PersonEntity:
          Name:
            NameFull: Viardot A
      – PersonEntity:
          Name:
            NameFull: McMillan A
      – PersonEntity:
          Name:
            NameFull: Dal MS
      – PersonEntity:
          Name:
            NameFull: Pereira J
      – PersonEntity:
          Name:
            NameFull: Kim JS
      – PersonEntity:
          Name:
            NameFull: Qiu L
      – PersonEntity:
          Name:
            NameFull: Batlevi CL
      – PersonEntity:
          Name:
            NameFull: Ibrahim R
      – PersonEntity:
          Name:
            NameFull: Hernandez J
      – PersonEntity:
          Name:
            NameFull: McCall B
      – PersonEntity:
          Name:
            NameFull: Jiang Y
      – PersonEntity:
          Name:
            NameFull: Yan M
      – PersonEntity:
          Name:
            NameFull: Harris W
      – PersonEntity:
          Name:
            NameFull: Musick L
      – PersonEntity:
          Name:
            NameFull: Haioun C
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 06
              M: 07
              Text: 2026 Jul 06
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1527-7755
          Titles:
            – TitleFull: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
              Type: main
ResultId 1